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Abstract
Pertussis (whooping cough) is frequently complicated by concomitant infections with respiratory viruses. Here we report
the effect of Bordetella pertussis infection on subsequent influenza virus (PR8) infection in mouse models and the role of
pertussis toxin (PT) in this effect. BALB/c mice infected with a wild-type strain of B. pertussis (WT) and subsequently (up to 14
days later) infected with PR8 had significantly increased pulmonary viral titers, lung pathology and mortality compared to
mice similarly infected with a PT-deficient mutant strain (DPT) and PR8. Substitution of WT infection by intranasal treatment
with purified active PT was sufficient to replicate the exacerbating effects on PR8 infection in BALB/c and C57/BL6 mice, but
the effects of PT were lost when toxin was administered 24 h after virus inoculation. PT had no effect on virus titers in
primary cultures of murine tracheal epithelial cells (mTECs) in vitro, suggesting the toxin targets an early immune response
to increase viral titers in the mouse model. However, type I interferon responses were not affected by PT. Whole genome
microarray analysis of gene expression in lung tissue from PT-treated and control PR8-infected mice at 12 and 36 h post-
virus inoculation revealed that PT treatment suppressed numerous genes associated with communication between innate
and adaptive immune responses. In mice depleted of alveolar macrophages, increase of pulmonary viral titers by PT
treatment was lost. PT also suppressed levels of IL-1b, IL-12, IFN-c, IL-6, KC, MCP-1 and TNF-a in the airways after PR8
infection. Furthermore PT treatment inhibited early recruitment of neutrophils and NK cells to the airways. Together these
findings demonstrate that infection with B. pertussis through PT activity predisposes the host to exacerbated influenza
infection by countering protective innate immune responses that control virus titers.
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Introduction
In 2010 the California Department of Public Health declared a
pertussis epidemic across California, the worst the state has seen in
63 years, with over 9400 cases and 10 infant deaths [1,2]. The
resurgence of pertussis or whooping cough in vaccinated
populations poses a significant public health concern, especially
for cases of mixed respiratory infections with viruses [3,4]. Mixed
respiratory infections can present with more severe disease,
including acute bronchiolitis, viral pneumonia and infant respira-
tory distress syndrome (IRDS), resulting in loss of pulmonary
function [5,6,7,8]. Several pathogenic viruses, including adenovi-
rus, rhinovirus and influenza virus, have been detected in the
airways of patients with confirmed pertussis [9,10,11,12,13].
Infants under 4 months are at greatest risk for coinfection with
respiratory syncytial virus (RSV), which can be fatal
[6,14,15,16,17]. Analysis of sputum and nasal aspirates from
acute and convalescent phase pertussis patients indicates that the
rate of viral co-infection can be as much as 30% in adult
populations and 16% in infants, and infection with more than one
virus is common [1,9,12,18]. However the actual rate of viral co-
infection with B. pertussis is believed to be higher, but has been
difficult to determine because these types of infections are
frequently found by chance and often go undiagnosed or
unreported [9,19]. The high prevalence of viral infections and
associated pathological conditions supports the theory that B.
pertussis predisposes to such infections, possibly through the effects
of its virulence factors [3,5,10].
Pertussis toxin (PT) is a multisubunit exotoxin produced
exclusively by B. pertussis that ADP-ribosylates G proteins in
mammalian cells to disrupt multiple G protein-coupled receptor
signaling pathways [20,21]. Recent studies on the role of PT
during infection suggest that this toxin has long lasting effects on
the immune system that could potentially benefit an ensuing viral
pathogen [22,23]. Using a mouse model of respiratory tract
infection, we previously found that PT is required early during the
bacterial infection [24]. Compared to a wild type infection, PT-
deficient B. pertussis had reduced bacterial loads by 24 h post-
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prior to inoculation with the PT-deficient B. pertussis strain
enhanced the bacterial infection, but not when administered
24 h post-inoculation. We also demonstrated that PT targets
resident alveolar macrophages (AMs) to enhance the bacterial
infection, since depletion of AMs allowed the PT-deficient B.
pertussis strain to grow to wild type numbers [25]. A single dose of
PT administered intranasally to mice modified the G proteins of
AMs for up to 2 weeks, which was equivalent to the duration of the
enhancing effect of PT treatment on the bacterial infection,
demonstrating its long lived effect [25]. In addition, PT has been
shown to inhibit early inflammatory responses in the respiratory
tract, which reduces neutrophil recruitment in response to B.
pertussis infection [26,27], and PT stimulates inflammatory
responses at the peak of infection by inducing Th1- and Th17-
associated cytokines, including gamma interferon (IFN-c) and IL-
17 [28]. The toxin has also been shown to suppress levels of serum
antibody to B. pertussis antigens after infection of mice [29], reduce
expression of major histocompatibility complex class II molecules
on the surface of human monocytes [30], and modulate expression
of surface markers on dendritic cells [31]. We hypothesize that
these effects, and those still unknown, allow PT to compromise
host immune responses and may contribute to a reduced ability to
combat a subsequent or concomitant influenza virus infection.
Influenza is a highly contagious respiratory infection that can
cause significant morbidity and mortality [32,33]. Many factors can
affect the severity of influenza infection, including the virulence of
the virus, immune status and age of the host, and whether a person
smokes [34,35]. Influenza virus can also synergize with other
pathogens in the respiratory tract to induce more severe disease
[36,37,38,39]. During the 1918 influenza pandemic, around 40
million people died. Some deaths appeared to be due to viral
pneumonia, however clinical and pathological evidence indicates
that the vast majority of people succumbed to secondary bacterial
pneumonia [40]. Animal studies have shown that influenza
infection preceding a respiratory bacterial challenge can result in
a life-threatening secondary pneumonia [36,41,42]. A number of
mechanisms have been proposed to explain how influenza
predisposes the host to superinfection with an unrelated or
heterologous pathogen. Recently investigators have described how
host responses associated with protection against influenza can
sensitize the host to secondary bacterial infections by inhibiting
antibacterial responses. IFN-c induced in response to influenza
inhibits AM function by reducing expression of the class A
scavenger receptor MARCO, inhibiting bacterial clearance [43].
Type I IFNs induced by influenza can also negatively impact the
host by impairing production of neutrophil chemoattractants KC
and MIP-2 following secondary challenge with Streptococcus pneumo-
niae, resulting in inadequate neutrophil responses during the early
phase of host defense against secondary bacterial infection [44].
Neutrophilic inflammation driven by the chemokine MIP-2 also
appears to be a determinant for influenza superinfection with
Bordetella parapertussis [42].
Influenza infection models in which the order of pathogen
administration has been reversed, with the bacterial infection
preceding influenza, have been less studied but indicate that the
bacterial infection can have varied effects depending on the species.
For example, proteases produced by Staphylococcus aureus and Aerococcus
viridans enhance influenza replication and pathogenicity in mice by
increasing cleavage of influenza virus HA, which is required for virus
release [45,46], and Serratia marcescens facilitates HA cleavage
activation indirectly by generating plasmin from plasminogen [47].
In contrast, infection with S. pneumoniae prior to influenza has been
shown to protect and improve survival against influenza challenge.
Pretreatment of mice with a lysate of non-typeable Haemophilus
influenzae (NTHi) that induces inflammation protected mice from a
lethal infection with influenza A/Hong Kong/8/68 (H3N2) [48].
Treatment with whole cell B. pertussis vaccine (killed cells) renders
mice resistant to mouse adenovirus and rabies virus, but is
contraindicated for infections with influenza virus and RSV
[49,50,51]. Studies examining mechanisms of interactions between
live B. pertussis and other viral pathogens in the airways have been
limited. Recently a group reported that infection with an attenuated
strain of B. pertussis, expressing inactive PT, protects mice against
highly pathogenic influenza A viruses by dampening the cytokine
storm [52]. The present study establishes a model for investigating
the interaction between B. pertussis and influenza virus and tests the
hypothesis that PT activity sensitizes the host to exacerbated virus
infection. We find that intranasal administration of B. pertussis or PT
prior to influenza virus increases viral load at early and later stages
of infection and also increases lung pathology and mortality
associated with the viral infection, demonstrating that a respiratory
bacterial infection can exacerbate a subsequent virus infection
through the enzymatic activity of a virulence factor, PT, which
targets host G protein-coupled signaling. We also find that PT
suppresses early innate host responses necessary to control the viral
infection. The exacerbation of respiratory viral infections by
pertussis is a potentially important public health issue and
underscores the need for pertussis vaccination for people of all ages.
Results
Effect of B. pertussis infection on subsequent influenza
virus infection and the role of PT
To assess the effects of B. pertussis infection and the role of PT on
secondary infection with influenza virus, BALB/c mice were
inoculated intranasally with 5610
5 colony forming units (CFU) of
B. pertussis (WT) or a mutant strain deficient in PT (DPT). Control
mice were equivalently inoculated with PBS. Bacterial loads in the
lungs assayed 4 days post-bacterial inoculation (n=3) showed
efficient infection (data not shown; WT=4.4610
6 CFU,
DPT=5.6610
5 CFU). Seven days post-bacterial inoculation the
mice were inoculated intranasally with 600 plaque-forming units
(PFU) of a mouse-adapted influenza A/PR/8/34 (PR8) virus.
Viral load in the lungs, weight loss (which is characteristic for
influenza virus infection) and mortality were evaluated over the
course of 10 days after virus inoculation (Fig. 1). Influenza-infected
mice began losing weight by day 4 and showed signs of lethargy,
wasting and ruffled fur. Weight loss was similar in all groups until
day 8 (,20%), but by day 10 the DPT-infected mice began to
recover while the control group and the WT-infected mice
continued to lose weight (Fig. 1C). On days 1, 3, 5, 7 and 10 post–
viral inoculation, groups of mice (n=3) were euthanized for
determination of viral load from whole lung tissue. Viral load in
the PBS control group peaked on day 3 post-inoculation at
3.9610
5 TCID50/ml and virus was cleared by day 10 (Fig. 1A).
DPT-infected mice had a viral load profile similar to the PBS
control group. However, viral load in WT B. pertussis-infected mice
was significantly higher than that of the other groups on day 3
(3.3610
6 TCID50/ml, P=0.0261) and on day 7 (2.4610
5,
P=0.047) post-inoculation (Fig. 1A). Furthermore, significantly
greater mortality was observed in WT-infected mice (75%,
P=0.0429) than in PBS control mice (Fig. 1B). DPT infection
enhanced mortality but to a lesser extent (25%, not significant vs.
control mice). Infection with WT B. pertussis, but not with DPT,
also increased overall lung pathology of the virus infection, as
measured by total protein concentration in BAL fluid (data not
shown). The B. pertussis-mediated increase in mortality associated
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bacterial loads, since there was no increase in WT B. pertussis
numbers in virus-infected mice, either when virus was inoculated 7
days after the bacteria (Fig. 1D) or when virus was co-inoculated
with the bacteria (Fig. 1E). B. pertussis DPT numbers were also
unaffected by virus infection (data not shown). Collectively, these
data demonstrate that prior infection with B. pertussis exacerbates
influenza virus infection in a PT-dependent manner. The presence
of PT in the WT B. pertussis infection has at least two effects on the
influenza infection; (1) it increases virus titers in the airways; and
(2) it enhances mortality.
Longevity of B. pertussis exacerbation of influenza virus
infection
To examine the longevity of B. pertussis exacerbation of influenza
virus infection, mice were inoculated intranasally with WT or DPT
B. pertussis (5610
5 CFU) or PBS as a control and groups of infected
and control mice were inoculated with PR8 virus (600 PFU) at
different times post-bacterial inoculation (day 0, 3, 7, 14 and 21).
Mice were weighed daily to confirm and follow the viral infection
(data not shown). Six days post-viral inoculation mice were
euthanized for assessment of viral load in the lungs. As expected,
levels of virus in PBS-treated control mice were comparable at all
time points (,10
5 TCID50/ml) (Fig. 1F). Viral titers in DPT-
infected mice were similar to thoseinPBScontrolmiceexceptwhen
virus was inoculated on day 3 post–bacterial inoculation, where the
titerswerelower(Fig.1F).WTinfectionsignificantly enhancedvirus
growth (compared to DPT infection) when virus was inoculated on
days 0, 3 and 7 post-bacterial inoculation and on days 0 and 7
compared to PBS control mice (Fig. 1F). The enhancing effect of
WT infection was lost by day 14 post-bacterial inoculation and viral
titers in WT-infected mice were significantly lower than in the other
Figure 1. Influenza virus infection in B. pertussis-infected mice and effect of PT. BALB/c mice were inoculated with WT or DPT B. pertussis
(5610
5 CFU) or PBS and seven days later infected with influenza virus PR8 (600 PFU). (A) Mean pulmonary viral titers, (B) survival rate, and (C) weight
changes were assessed for 10 days post virus inoculation. (D, E) Bacterial loads in virus-infected and control mice at the indicated time points, when
virus was inoculated (D) 7 days after bacterial inoculation, or (E) concomitantly with bacteria. (F) Mean pulmonary viral titers (day 6 post virus
inoculation) in mice inoculated with WT or DPT B. pertussis and infected with influenza PR8 (600 PFU) at the indicated times post B. pertussis
inoculation. n=3–4 mice/treatment group/time point (4–5 mice for the last time point in A–C). *Significantly different from control (P,0.05).
doi:10.1371/journal.pone.0019016.g001
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(Fig. 1F), suggesting that the immune responses elicited by PT-
producingB. pertussis during the later stages of the bacterial infection
may be protective against virus infection. Together these data
demonstrate that B. pertussis, through the action of PT, alters the
lung environment in a manner that promotes virus growth early
after bacterial infection and for a limited time (1–14 days).
Effect of purified PT administration on influenza virus
infection
The results shown in Fig. 1 suggested that PT may be the factor
responsible for B. pertussis exacerbation of influenza virus infection.
Therefore, we tested whether purified PT, through its inhibitory
activity on G protein signaling, could replicate the enhancing
effect on virus titers in the airways independently of the bacteria.
However, binding of the PT B oligomer (PTB) to cell surface
molecules can elicit several intracellular signaling events indepen-
dent of the enzymatic activity of the toxin A subunit [53].
Therefore, to determine if any observed differences in influenza
virus titers caused by PT are due to its enzymatic activity or to the
toxin’s binding and signaling properties, mice were pretreated with
active (PT) or inactive PT-9K/129G (PT*) toxin and infected with
PR8 virus. PT* is structurally similar to active PT, but has 2
mutations in the A subunit that render it enzymatically inactive,
which makes it an ideal control to distinguish between effects due
to G protein ADP-ribosylation and other binding/signaling effects.
Groups of BALB/c mice (n=3) were inoculated intranasally with
100 ng PT or PT*, or an equal volume of PBS as a control, and
24 h later these mice were inoculated intranasally with 600 PFU
of PR8. The mice were euthanized on days 1, 3, 5, 7 and 9 post-
virus inoculation for assessment of virus infection and disease. As
shown in Fig. 2A, control mice had a viral load that peaked on day
3 with a mean viral titer of 9.2610
5 TCID50/ml. Virus load
decreased over the next few days and was cleared by day 9. PT*-
treated mice had a viral load profile similar to the PBS-treated
mice. In contrast to the controls, PT had an early enhancing effect
on virus load. By day 1, PT treatment enhanced viral load by 140-
fold over the control group (P=0.018). The enhancing effect on
virus titers persisted over the course of infection and the peak
shifted from day 3 to day 5. PT treatment resulted in the death of
all virus-infected mice by day 9, whereas none of the PT*-treated
mice died by this time (Fig. 2B, P=0.0202). However weight loss
was not significantly different between groups (Fig. 2C). In a
further investigation of the effect of PT on virus-associated
mortality, groups of BALB/c mice (n=8) were treated intranasally
with 100 ng of PT or an equal volume of PBS as a control and
24 h later inoculated with a moderate dose (500 PFU) or a high
dose (1500 PFU) of influenza virus PR8. No significant differences
in weight loss were observed between groups (Fig. S1B and D).
Mice pretreated with PBS and inoculated with 500 PFU of virus
had a mortality rate of 50% by day 21 (Fig. S1A). In contrast,
pretreatment with PT significantly reduced the survival rate, with
no mice surviving past day 17 (P=0.0421). At the higher dose of
virus, none of the mice survived beyond day 10 (Fig. S1C);
however the onset of death was 3 days earlier in the PT-treated
group (P=0.0286). Together these data demonstrate that, in
addition to exacerbating other aspects of influenza infection and
disease, PT significantly increases influenza mortality.
To determine whether the effect of PT in enhancing viral
infection and disease could be reproduced in a different mouse
Figure 2. Effect of PT enzymatic activity on influenza infection in BALB/c and C57BL/6 mice. Mice were intranasally treated with 100 ng
purified PT or PT-9K/129G (PT*) or PBS and infected with influenza virus PR8 (600 PFU) 24 h later. Mean pulmonary viral titers, survival rate and
weight changes in BALB/c (A–C) and C57BL/6 (D–F) mice assessed for 9–13 days post virus inoculation. n=3 mice/treatment group/time point (4–5
mice for the last time point for survival assessment). *Significantly different from control (P,0.05).
doi:10.1371/journal.pone.0019016.g002
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treated with either PT or PT*. As shown in Fig. 2D, viral load
peaked in the control and PT*-treated mice on day 3 post-
inoculation and virus was cleared around day 9. PT treatment
shifted the peak viral titer earlier to day 2 post-inoculation
(4.6610
6 vs 6.1610
4 TCID50/ml, PT vs PBS), and delayed viral
clearance on day 7. PT treatment significantly increased mortality
of the virus infection over the other groups (P=0.0013), and on
day 9 all of the PT-treated mice were dead (Fig. 2E). In contrast,
only one PT*-treated mouse died by day 9 (and 2 by day 13).
Weight loss was not significantly different between groups over the
first 9 days of virus infection (Fig. 2F). Together, these data
demonstrate that only enzymatically active PT has an exacerbat-
ing effect on influenza disease. The effect was very similar in two
different mouse strains, both of which experienced an early
increase in viral titers and increased mortality as a result of PT
treatment, ruling out the possibility that the effect was a peculiarity
of a particular genetic background.
To assess changes caused by PT treatment on virus-induced
lung pathology, total protein concentration in bronchoalveolar
lavage (BAL) fluid of virus-infected, PT-treated, and control mice
on days 2, 6 and 8 post-inoculation was measured by protein assay.
The protein concentration was significantly higher in the BAL
fluid of PT-treated virus-infected mice than in that of PBS-treated
virus-infected mice or PT-treated uninfected mice on days 6 and 8
post-inoculation (Fig. S2). To further assess the impact of PT on
lung pathology associated with influenza virus infection, lung
sections from PR8-infected mice previously inoculated with PT or
PBS were harvested on days 3 and 6 post-viral inoculation and
analyzed by microscopy after staining with hematoxylin and eosin
(Fig. 3). At day 3 post-inoculation, control virus-infected mice
showed mild inflammation and sparse interstitial infiltrates
(Fig. 3C) that increased on day 6 (Fig. 3D). PT-treated virus-
infected mice were similar to PBS control mice on day 3 post-
inoculation (Fig. 3C and 3E) but showed increased inflammatory
cell infiltration, peribronchial cuffing and edema on day 6 (Fig. 3D
and 3F). PT treatment alone without virus infection does not
induce any significant lung pathology (our unpublished data).
These data demonstrate that intranasal treatment with purified PT
enhances the pathological manifestations of influenza, in addition
to increasing the viral burden and mortality, replicating the effect
of WT B. pertussis infection.
We next assessed the longevity of the enhancing effect of PT,
independent of the bacterial infection, in C57/BL6 mice. The
results in Fig. 1F suggested that B. pertussis, through the activity of
PT, provides influenza virus a window of opportunity that
sensitizes the host for at least 7 days. Accordingly, we compared
influenza virus infection in groups of C57BL/6 mice intranasally
inoculated with 100 ng of PT or PT*, or with an equal volume of
PBS as a control. At days 1, 7, 14 and 21 post-treatment, groups
of mice (n=3) were inoculated with 600 PFU of PR8. Lungs
were harvested 2 days post-virus inoculation and viral titers were
determined. This time point was chosen because it was the one at
which PT showed the greatest effect in C57BL/6 mice (Fig. 2D).
Fig. 4A shows that the mean virus titers in the lungs were
significantly higher in PT-treated mice than in PT*-treated mice
on days 1, 7 and 14 (and over the PBS control mice on days 1
and 7). There was still some enhancing effect of PT on day 21
post-treatment, though this was not quite significant (P=0.087 vs.
PT*-treated group). These results demonstrate that PT has a
long-lasting enhancing effect on influenza virus titers that is
dependent on its enzymatic activity but independent of the
bacterial infection.
Effect of prior or delayed administration of purified PT on
influenza virus infection
Since the previous experiment established that administration of
PT up to 7 days prior to influenza virus inoculation provided the
virus a significant advantage over the PBS control (Fig. 4A), we
tested whether PT treatment concomitant with or subsequent to
virus inoculation also had an effect. Prior studies demonstrated the
ability of PT to enhance B. pertussis respiratory tract infection when
administered up to 14 days prior to bacterial inoculation, but not
when administered 24 h after inoculation [24]. Therefore we
tested whether the timing of PT inoculation has a similar effect on
influenza viral infection by comparing the mean viral titers in the
lungs of mice treated with 100 ng of PT intranasally 24 h before,
concurrently with, or 24 h after virus inoculation. PT treatment
was coordinated so that all mice were inoculated with influenza
virus on the same day with the same dose (600 PFU). Lung tissue
was harvested on days 2, 4, and 6 post-virus inoculation and mean
pulmonary viral titers were determined. As seen in Fig. 4B, PT
treatment prior to virus inoculation significantly enhanced viral
load over the PBS control mice on day 2 (6.7610
5 TCID50/mL,
P=0.0231) and day 4 (8.3610
4 TCID50/mL, P=0.047).
Figure 3. Histopathological examination of lungs from PT-
treated and control mice infected with influenza virus. Lung
sections of BALB/c mice inoculated with 100 ng of PT or with PBS and
infected with influenza PR8 (600 PFU) 24 h later. Sections were prepared
from (A–B) uninfected mice, or 3 and 6 days after virus inoculation from
(C–D) PBS-treated or (E–F) PT-treated mice. Lungs were harvested and
fixed immediately in 4% formalin. Sections were stained with hematox-
ylin-eosin and evaluated for density and location of cellular infiltrates.
Sections include representative results from 3 mice/time point. Original
magnification 106. n=3 mice/treatment group.
doi:10.1371/journal.pone.0019016.g003
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Co-inoculation of the toxin with the virus significantly increased
viral titers on day 4 (3.7610
7 TCID50/mL, P=0.0421) and day 6
post-infection (8.3610
4 TCID50/mL, P=0.0470) (Fig. 4C). In
contrast, no enhancing effect on viral titers was observed when PT
was administered 24 h after virus inoculation (Fig. 4D). Together
these data indicate that PT is capable of suppressing early events
(0–24 h post-virus inoculation) that allows virus to replicate to
higher levels in the mouse lungs.
Effect of PT on influenza virus replication in vitro
Since our results thus far indicated that PT increases virus titers
in vivo early after infection, we sought to address the question of
whether PT directly enhances influenza virus replication in mouse
airway cells. To this end we expanded our study to examine the
replication of a recombinant H1N1 influenza virus strain A/
WSN/33 (WSN) that has been shown to replicate efficiently in
primary murine tracheal epithelial cell (mTEC) cultures over
several days [54]. First we confirmed that PT still maintained an
enhancing effect on this different influenza virus in mice. BALB/c
mice (n=3) were pretreated with 100 ng of PT or an equal volume
of PBS and 24 h later inoculated with 500 PFU of WSN. Lungs
were harvested 3 days post-inoculation and viral titers were
determined. Treatment with PT significantly increased the
pulmonary mean virus titer from 5.5610
3 to 7.7610
5 TCID50
(P=0.0191) (Fig. 5A). Next mTEC cultures (n=3) were treated
with PT (1 nM or 5 nM) or PT* (5 nM) for 24 h, or left untreated.
Cells were then washed with medium and infected with WSN at
an MOI of approximately 0.001. After 1 h incubation, the
inoculum was removed, and the cells were washed with medium
and incubated at 37uC. MTECs were sampled on days 1, 2, 3, 4,
and 5 post-infection and virus titers were determined. As seen in
Fig. 5B, PT had little or no effect on viral titers up to and including
day 5 post-infection at either concentration. This was similar for
cells infected with PR8 (data not shown). Together these data
indicate that PT does not enhance virus replication at the cellular
level in vitro even though it can enhance viral titers in vivo,
consistent with the idea that PT suppresses the immune response
to allow the virus to replicate to higher levels.
Effect of PT on the early type I interferon response to
influenza
To better understand the potential influences PT has on the
early phase of influenza virus infection, we analyzed the effect of
PT treatment on the type I interferon (IFN) response to influenza
virus infection. Type I IFNs IFN-a and IFN-b are cytokines with
essential roles in innate viral immunity induced soon after
influenza infection [55,56]. Many viruses and some bacteria have
acquired effective strategies to obstruct IFN activity [57,58,59,60].
We hypothesized that PT could be working in a similar fashion to
enhance influenza viral titers early after infection by preventing any
of three events: IFN production, downstream signaling after IFN
binding to its receptor, or expression of IFN-stimulated genes. To
this end we assessed production of IFN-a in the airways of mice
treated with PT and infected with influenza virus. BALB/c mice
were treated intranasally with 100 ng of PT or given an equal
volume of PBS as a control and inoculated with 600 PFU of PR8
24 h later. BAL supernatants were collected from infected animals
at 1, 2, and 3 days post-virus inoculation and assayed by ELISA for
the presence of IFN-a (Fig. S3A). Equivalent levels of IFN-a
appeared in the BAL fluid of both groups of virus-infected mice at
day 2 post-inoculation and declined for the control group at day 3.
Figure 4. Effect of prior, concurrent and delayed PT treatment on influenza. (A) C57BL/6 mice were intranasally treated with 100 ng of PT,
PT* or with PBS and infected with influenza PR8 (600 PFU) at the indicated times post PT treatment. Mean pulmonary viral titers were determined 2
days post-virus inoculation. (B–D) Mean pulmonary viral titers of mice treated with 100 ng of PT or PBS (control) 24 h prior (B), concurrently with (C),
or 24 h post (D) infection with influenza PR8. Titers were determined 2, 4 and 6 days post virus inoculation. n=3 mice/treatment group. *Significantly
different from control (P,0.05).
doi:10.1371/journal.pone.0019016.g004
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significantly higher than in control mice (322 vs. 122 pg/mL,
P=0.0212), suggesting that PT treatment sustained the expression
of IFN-a. However, further examination of type I IFN expression in
PT-treated and control virus-infected mice by a type I IFN
bioactivityassay,whichmeasures anti-viralactivityofalltype I IFNs
produced,demonstrated that PT has no effect onthekineticsoftype
I IFN expression during 8 days post-virus inoculation (Fig. S3B).
Therefore, PT does not appear to inhibit type I IFN production to
increase early viral titers. In addition, we examined the level of
tyrosine phosphorylation of STAT1 (signal transducer and activator
of transcription) in A549 cells, widely used to study virus-IFN
interactions [61,62], to determine whether the observed effects of
PT on virus titers might be dueto altered typeI IFNsignaling. A549
cells were treated with PT (1 nM) for 24 h and stimulated with
1000 U of human IFN-a A/D. PT treatment resulted in modestly
reduced tyrosine phosphorylation of STAT1 at 15 and 30 min post
IFN-stimulation as judged by immunoblotting (Fig. S3C and D),
however the phosphorylation level was equal during the peak of
signaling at 45–60 min. These data indicate that inhibition of
tyrosine phosphorylation of STAT1 by PT treatment is unlikely to
account for the increased virus titers in mice. ISG15 is an ubiquitin-
like protein rapidly induced in response to virus infection and IFN
treatment [63]. Mice lacking ISG15 have increased susceptibility to
influenza, herpes virus type 1, and Sindbis virus infection [64]. We
therefore examined the expression pattern of soluble ISG15 and
ISG15-protein conjugation in A549 cells with or without PT
treatment (1 nM) and infected with influenza virus at an MOI=1.
Cell lysates were subjected to western blot analysis using anti-ISG15
antibody. Protein bands detected in control samples were similar to
bands detected in PT-treated cells (Fig. S3E and F). Similar findings
were made in cells treated with IFN (data not shown), together
indicating that PT does not affect the expression of the IFN target
protein ISG15 or its conjugation to other proteins. Together these
data indicate that the type I IFN pathway does not appear to be a
significant target for PT inhibition leading to increased viral titers.
Microarray analysis of PT effects on influenza virus-
induced pulmonary gene expression early after infection
Taking another approach to understand how PT treatment
enhances viral titers during the early phase of influenza infection,
we used gene expression analysis to provide a global view of the
host response in lungs of infected mice. Whole genome expression
microarray analysis was performed on total RNA isolated from
lungs of mice treated intranasally with 100 ng of PT and infected
with 600 PFU of influenza PR8 virus, compared to RNA from
lungs of control mice treated with an equal volume of PBS and
infected with an equal dose of PR8. Lungs from three mice for
each treatment were harvested at 12 h and 36 h post virus
inoculation (total n=12). The fold change of virus-induced gene
expression levels in PT-treated mice compared to control mice was
averaged from the three mice per group, and averaged gene
expression data was filtered using a cut-off value of 1.5-fold up- or
down-regulation and a statistical significance of P,0.05. A total of
27 genes at 12 h and 51 genes at 36 h post-inoculation in PT-
treated mice showed at least 1.5-fold difference in expression level
compared to control infected mice (Table 1). The majority of PT-
mediated changes in gene expression at 12 and 36 h post-infection
were down-regulation, with 81% and 92% of the total, respectively
(Table 1), indicating that PT has a significant suppressive effect on
virus-induced gene expression.
To characterize the functional consequences of gene expression
changes associated with PT treatment and influenza infection, we
performed pathway analysis of the gene expression data with
Ingenuity Pathways Analysis. As shown in Table S1, this analysis
revealed that PT treatment resulted in the most significant changes
to antigen presentation, cell-to-cell signaling and interaction, gene
expression, hematological system development and function,
immune cell trafficking, inflammatory response and tissue
morphology functions. These data show that PT alters the
expression of a substantial number of genes that results in a
decrease in pro-inflammatory and cell recruitment responses.
Pathway analysis showed that, among the PT-affected genes, 5
Figure 5. Effect of PT on influenza WSN virus infection in BALB/c mice and on mTECs. (A) Groups of BALB/c mice (n=4) were pretreated
with 100 ng of PT or an equal volume of PBS and 24 h later inoculated with 500 PFU of influenza WSN virus. Mean pulmonary viral titers were
determined 3 days post virus inoculation. (B) mTECs (3 wells per group) were treated with 1 nM or 5 nM PT or 5 nM PT* for 24 h, or left untreated.
The cells were then washed and infected with WSN virus at an MOI of approximately 0.001. After 1 h incubation, the inoculum was removed, and the
cells were washed with medium and incubated at 37uC. At the indicated times, the infected-cell supernatant was sampled, and infectious virus titers
were determined by TCID50.
doi:10.1371/journal.pone.0019016.g005
Table 1. Numbers of genes differentially regulated in lungs of





12 h 5 22 27
36 h 4 47 51
aGenes with a fold change greater than 1.5 (P,0.05) of PT-treated group over
controls.
doi:10.1371/journal.pone.0019016.t001
B. pertussis Exacerbates Secondary Influenza
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19016pathways were significantly enriched at 36 h post virus inocula-
tion, including several relating to some of the ascribed functions of
AMs in response to influenza (Table 2). For example, the down-
regulation effect of PT treatment is characterized by a suppression
of genes related to communication between innate and adaptive
immune cells, Fcc receptor-mediated phagocytosis in macrophag-
es and monocytes, antigen presentation and the role of
hypercytokinemia/hyperchemokinemia in the pathogenesis of
influenza pathways. Host genes with the highest fold changes
between PT-treated and control virus-infected mice at 12 h (Table
S2) and 36 h (Table S3) post-virus inoculation also support the
hypothesis that innate immune responses and AMs are targets for
PT suppression, and provide a basis for specific gene targets for
future analysis. The lack of type I IFN-associated genes in this list
confirmed our experimental observations from the previous
section (Fig. S3). Collectively these data indicate that PT treatment
prior to influenza infection suppresses a wide range of genes
associated with numerous innate immune responses without
specifically targeting one pathway over another. This subset of
differentially regulated genes, however, relates closely to biological
functions and cellular pathways of AMs, which play a critical role
in regulating pulmonary immune responses to influenza viruses
[65,66,67,68], suggesting that PT reduces their capacity to
respond to the virus and direct the ensuing innate and adaptive
immune response.
Depletion of AMs eliminates the exacerbating effect of
PT
Since the microarray analysis implicated an association between
PT treatment and AM dysfunction, we investigated the role of
these cells by depleting them before PT treatment and infection
with influenza virus. Depletion of AM was achieved by intranasal
instillation of 100 ml of clodronate liposomes (CL) and control
mice were administered an equal volume of PBS-liposomes (PL).
CL administration resulted in an 86% reduction in AM numbers
in BAL samples 2 days post-administration, compared to PL-
treated mice (Fig. 6A). Groups of the CL- and PL-treated mice
(n=8) were then administered either 100 ng of PT or an equal
volume of PBS and inoculated with the standard dose of influenza
24 h later. Lung tissues were collected for determination of viral
titers at 2 and 4 days post virus inoculation (Fig. 6B). The mean
pulmonary viral titer in PT-treated mice of the PL-group was 1.4
log higher on day 2 (P=0.049) and 1 log higher on day 4
(P=0.1324) compared to PBS-treated mice, typical of the
exacerbating effect of PT on viral titers. Depletion of AMs
abrogated the enhancement of viral titers by PT at both time
points. We conclude that PT inactivation of the protective activity
of AMs contributes to the increase in viral titers during the early
phase of influenza infection.
AMs and lung epithelial cells coordinate the expression of many
cytokines and chemokines to recruit and activate protective
immune cells to the airways in response to influenza virus
infection [66,69]. Based on the pathway analysis findings from the
microarray study, we hypothesized that PT would suppress
recruitment of immune cells to the airways by reducing the
expression of proinflammatory cytokines and chemokines. To test
Table 2. Pathways significantly affected by PT pretreatment in influenza virus-infected mice at 36 h post-inoculation.
Pathway Name
a p-value Gene Count
b
Communication between Innate and Adaptive Immune Cells 1.12E205 5/83
Fcc Receptor-mediated Phagocytosis in Macrophages and Monocytes 1.31E203 3/91
Antigen Presentation Pathway 2.11E203 2/29
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza 2.25E204 3/31
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 3.35E203 3/79
aBiological pathways analysis identified by Ingenuity Pathways Analysis library of canonical pathways that were most significant to the data set.
bRatio of genes in a canonical pathway differentially regulated by PT treatment.
doi:10.1371/journal.pone.0019016.t002
Figure 6. PT targets AM to enhance early viral titers and
suppresses early pro-inflammatory airway responses. Groups of
BALB/c mice were intranasally inoculated with 100 mL clodronate
liposomes (CL) to deplete AM or with PBS liposomes (PL) as a control.
(A) Percent of resident AM and neutrophils in the airways (BAL) two
days after CL and PL treatment. (B) CL- and PL-treated mice were
intranasally treated 2 days later with 100 ng of PT or an equal volume of
PBS and infected with influenza PR8 (600 PFU) virus 24 h after PT/PBS
treatment. Mean pulmonary viral titers were determined on days 2 and
4 post virus inoculation. n=4 mice/treatment group. *Significantly
different from control (P,0.05).
doi:10.1371/journal.pone.0019016.g006
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following PT or PBS treatment for 24 h and influenza virus
infection. BAL samples were recovered 2 days post virus
inoculation and assayed by multiplex array for levels of IFN-c,
IL-10, IL-12, IL-1b, IL-6, KC, MCP-1, RANTES and TNF-a
(Fig. 7A). Levels of RANTES and IL-10 were similar for both
virus-infected groups. However, the level of IFN-c was 2.7-fold
lower (P=0.0117) in PT treated mice than in control mice and
Figure 7. PT suppresses early pro-inflammatory responses in the airways. Groups of BALB/c mice were intranasally inoculated with 100 ng
of PT or an equal volume of PBS as a control and infected with influenza PR8 (600 PFU) 24 h later. Cytokine concentrations and cellular recruitment
was assessed two days after virus inoculation. (A) Lung (BAL) inflammatory cytokine levels assayed by multiplex bead array. (B) Numbers of lung
immune cell populations in BAL fluid of PT-treated (PT/PR8) or PBS control-treated (PR8) mice infected with influenza virus (and in untreated mice).
Neutrophils (CD11b
+, Gr1
hi), alveolar macrophages (CD11b
2, CD11c
+, F4/80
+), and NK cells (NK1.1
+). n=4 mice/treatment group. Significant
differences are indicated by P value.
doi:10.1371/journal.pone.0019016.g007
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PT treatment were highly significant (P,0.001). Next we
examined the early cellular populations in the airways following
PT or PBS treatment and influenza virus infection. BAL sample
infiltrates were collected 2 days post virus inoculation and
analyzed by flow cytometry (Fig. 7B). Consistent with the lower
levels of cytokines, PT treatment resulted in greater than 1 log
reduction in the number of infiltrating neutrophils (P,0.0001) and
NK cells compared with that in PBS control mice (P,0.001).
These data indicate that PT has an inhibitory effect on the early
recruitment to the airways of cells that play a significant role in
controlling virus replication and spread [70,71,72].
Discussion
Individuals with a compromised immune system due to drug
treatment, infection, old age and genetic disposition are at
increased risk of infection with influenza. Early events during
influenza infection dictate the outcome of the disease by
containing and preventing excessive proliferation of virus in the
respiratory tract, which is necessary for the adaptive immune
response to mount an effective retaliation against the invading
pathogen. B. pertussis is a bacterial airway pathogen that has
specifically evolved a strategy to survive in the sterile environment
of the human lungs by suppressing innate immune responses [23].
The virulence factor PT is very successful at suppressing innate
immune responses, including cell recruitment, chemokine expres-
sion and antigen presentation, to promote bacterial survival in the
respiratory tract. PT is unique from other bacterial toxins in that it
effectively shuts down G protein-coupled receptor signaling, which
is critical for important immune cellular function, and does this
without killing the cells. Chemokines and cytokines that signal
through G protein-coupled receptors are important for recruiting
and activating effector cells, i.e neutrophils, monocytes, NKs, and
T-cells, to the airways. Here we show that suppression of the
innate immune response by PT is effective at sensitizing the host to
a secondary respiratory pathogen. Infection with B. pertussis had a
profound effect on an ensuing influenza virus infection. Mice
inoculated with wild type B. pertussis (WT) and subsequently
infected with influenza virus (PR8) had increased pulmonary viral
titers at early, peak and clearance phases of infection, which was
not observed in mice inoculated with an isogenic strain of B.
pertussis deficient for PT (DPT). WT infection increased pulmonary
viral titers by more than one log on days 3 and 7 post–virus
inoculation and enhanced lung pathology associated with virus
infection, as seen in the increase in total protein recovered from
BAL samples and the destruction of lung architecture. We also
observed that infection with WT bacteria increased influenza
mortality 100% after 10 days of infection, which was not observed
in DPT-infected mice, together suggesting a role for PT in disease
exacerbation. Although we cannot formally rule out the possibility
that mortality was due to influenza virus exacerbation of B. pertussis
infection (rather than the other way around), this is very unlikely
since B. pertussis infection in immunocompetent mice is rarely
lethal, even at much higher bacterial loads than those seen in our
experiments, and PT treatment was able to replicate the increased
mortality effect.
Coadministration of B. pertussis and influenza virus increased
viral titers, as did infections of B. pertussis administered 7 days prior
to the virus. However, WT bacterial infection reduced influenza
when virus was administered after 21 days, lowering the viral titers
to almost undetectable levels and indicating that exacerbation of
influenza infection by WT bacteria was time dependent. This was
not seen in the DPT infection, indicating that PT may induce a
switch in the immune response between 7 and 21 days post-
bacterial inoculation that is beneficial for viral clearance. The host
immune response to WT infection is significantly altered during
this period. Following a respiratory challenge with B. pertussis the
number of neutrophils, NK and NKT cells are elevated [73] as are
the levels of IL-6, TNF-a, IFN-c and IL-17 in the lungs. It is
possible that one or a combination of these responses to the
bacteria help clear the virus more efficiently. Some of these
responses are indicative of Th1 immunity and are important for
clearance of influenza. Together these results suggest that PT
provides a window of opportunity that the virus can exploit for a
period of time equivalent to its enhancing effects on the bacterial
infection.
We also found that a single dose of purified PT administered
intranasally was able to replicate the exacerbating effects of B.
pertussis infection on influenza virus infection independent of the
bacteria. Intranasal treatment with 100 ng PT followed by
inoculation with PR8 7 days later significantly increased viral
titers when compared to PBS control-treated mice, and also
enhanced virus-associated lung pathology and increased mortality
(PT treatment alone has no pathological effects on mouse lungs –
our unpublished data). PT significantly increased the viral load
over the course of 9 days of viral infection, especially early after
inoculation and later after the peak, in both BALB/c and C57BL/
6 mice. Since PT-treated mice had relatively high viral titers at the
last time point sampled before death, it is not clear that these mice
were able to clear the infection, which may have been a
contributing factor to the enhanced mortality. Alternatively these
mice could have died through the induction of a hyperimmune
response (cytokine storm) which has been reported for more
pathogenic viruses. The exacerbating effect of a single dose of PT
on viral infection in C57BL/6 mice lasted at least 14 days, which is
roughly equivalent to the duration of its enhancing effects for B.
pertussis infection and the modifying effects observed on AM [25].
PT treatment alone does not induce inflammation or recruitment
of monocytes or neutrophils to the airways (our unpublished data)
and thus, without LPS stimulation from the bacteria, it is probable
that the AMs do not turn over and remain modified in the airways
and ineffective to respond to an invading pathogen. Since
pretreatment and co-treatment of mice with PT (relative to virus
inoculation) increased lung viral loads, but not PT treatment after
virus inoculation, this indicated that PT is targeting a component
of the early innate immune response with an important activity
within the first 24 h of virus infection. PT also increased influenza
viral titers of another influenza strain (WSN), demonstrating that
this effect is not a peculiarity of PR8 infection. However, PT
treatment of tracheal epithelial cell cultures did not significantly
enhance virus replication in these cells, suggesting that PT does
not directly increase cellular viral replication. Together these data
led us to hypothesize that PT affects early immune responses,
possibly anti-viral AM function, to enhance respiratory virus
infection.
The early increase in viral titers was not due to PT inhibition of
the type I IFN response. We had predicted that PT could increase
viral titers in the airways by suppressing type I IFNs because AMs
are the primary source of IFN-a in the airways in response to
RNA viruses [74] and PT has been shown to inhibit expression of
the cytokines TNF-a and IL-12 in monocyte-derived DC in a
cAMP-dependent manner [75]. However we observed little effect
on IFN expression in BAL samples of mice or cytokine signaling in
vitro through the JAK/STAT signaling pathway. Nor did we
observe a significant effect on the expression of the IFN-stimulated
gene ISG15, indicating that PT does not inhibit activation of the
type I IFN response nor does it interfere with the ability of ISGs to
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suppressing the innate immune response via another mechanism.
To get at this question we used microarray technology to assess the
effect of PT on immune responses to influenza in the whole lung,
and pathway analysis revealed that PT inhibits communication
between the adaptive and innate immune response, alters the
expression of cytokines/chemokine in response to influenza and
down regulates genes important for virus detection. Based on these
results we hypothesized that PT was targeting AMs, as these
pathways are associated with AM function. AMs are important for
controlling virus replication and orchestrating the immune
response, and they are an important source of chemokines and
cytokines such as type I IFNs, IFN-c, and TNF-a, which are
required for recruitment and activation of effectors [76].
Additionally, AMs are responsible for phagocytosing infected
epithelial cells [77] and antigen presentation to incoming CD8
cells, which ultimately clear the infection. Viral titer profiles and
survival rates were similar in both BALB/c and C57BL/6 mice,
which differ in the cytokine profile of their adaptive immune
response, again suggesting that PT mediates its effects before the
development of the adaptive response. We found that depletion of
AMs resulted in abrogation of the PT enhancement of viral titers,
supporting the hypothesis that PT targets AMs to increase virus
titers. Depletion of these cells before a sublethal infection with
1918 HA/NA:Tx/91 virus was shown to result in increased virus
growth, mortality and decreased expression of cytokines and
chemokines in mice [67]. Therefore it is tempting to speculate that
PT treatment is equivalent to depleting AMs prior to influenza
infection. Indeed, at day 4 post-inoculation we found that PT
treatment and AM depletion had equivalent enhancing effects on
viral titers. However, lack of a significant increase in viral titers at
day 2 by AM depletion in our experiments (Fig. 6B) would suggest
that this interaction is complex. One possible explanation for the
observed effect of PT (but not AM depletion) at day 2 is that PT
targets other cells, possibly airway epithelia, in addition to AMs to
increase viral titers.
We also found viral exacerbation to correlate with inhibition of
neutrophil and NK cell recruitment early in the viral infection, as
well as reduction in the levels of the chemokines KC (CXCL1) and
MCP-1 (CCL2), which are chemoattractants for these cells. Levels
of the cytokines TNF-a, IFN-c, IL-6, IL-12 and IL-1b were also
significantly reduced by PT treatment on day 2 post-viral
inoculation. These data would suggest that PT inhibits cell
recruitment and expression of Th1 cytokines early during
influenza infection. TNF and IL-1 (which were both down–
regulated by PT) produced by AM enhance chemokine-dependent
neutrophil and T cell transmigration across influenza virus-
infected epithelium [69,78,79]. Neutrophils play a critical role in
controlling influenza disease as depletion of these cells has been
shown to increase the mortality rate and pulmonary virus titers
from the early to the late phase after infection [70]. By suppressing
AM cytokine gene expression PT may be modulating the number
and function of other effector immune cells required for viral
clearance and controlling lung inflammation. However, in other
studies we have found that PT treatment before virus inoculation
increases the levels of several cytokines and chemokines later (day
4–8) in the virus infection, which may contribute to the increased
lethality (Ayala and Carbonetti, unpublished data). Therefore PT
may have a dual effect in exacerbating the virus infection – early
inhibition of immune effector cell recruitment and later stimula-
tion of damaging cytokine responses.
In conclusion, we have demonstrated that exacerbation of
influenza occurs if the host is already infected with B. pertussis.
While previous reports contraindicated pertussis vaccines for
influenza, in this study we show for the first time that the effect of
B. pertussis is attributable to the enzymatic activity of PT acting
locally to suppress the innate immune response. If the mouse model
is representative of human infections, the results of this study have
broad implications, especially for communities where pertussis is on
the rise. Undiagnosed pertussis infections could help spread an
emerging virus or cause viral pneumonia to take hold in otherwise
healthy individuals. Such a scenario may explain the observation of
an out-of-season influenza outbreak in a nursing home where
individuals had evidence of recent pertussis infection [10]. This
would further emphasize the importance of pertussis vaccination for
individuals at risk from influenza infections, including the elderly,
for whom pertussis vaccines have only recently become available.
Many immune processes are controlled or affected by G protein-
coupled chemokinesignaling, includingpathogen detection, cellular
activation, immune cell trafficking, and antigen presentation
[80,81,82,83,84]. Whether the effects of PT are pathway-specific
or the result of a more global inhibition has yet to be established.
Future work will examine the effect of PT on virus-induced
pathways, recruitment of effector cells and immune response gene
expression. Importantly this paper demonstrates a mechanism by
which B. pertussis can account for the high rate of coinfection with
viruses. The emergence of viruses such as the 2009 pandemic
influenza (pH1N1) virus in regions where B. pertussis is endemic
underscores the need for more studies like this to examine the
dynamics and mechanisms of interaction between B. pertussis and
other respiratory pathogens so that better vaccination strategies or
therapeutics can be developed to alleviate disease.
Methods
Bacterial Strains
The B. pertussis strains used for this study were streptomycin-
and nalidixic acid-resistant derivatives of Tohama I and were
produced as previously described [85]. The PT-deficient mutant
strain (DPT) contains an in-frame deletion of PT genes and the
wild-type (WT) strain is the parental strain that produces native
PT [24]. The PT-9K/129G (PT*) strain of B. pertussis produces PT
with 2 amino acid substitutions in the S1 subunit, rendering the
toxin enzymatically inactive and thereby unable to ADP-ribosylate
target Gi proteins [86]. B. pertussis strains were grown on Bordet-
Gengou (BG) agar plates containing 10% defibrinated sheep blood
and 400 mg/ml of streptomycin.
Pertussis Toxin
PT and PT* were purified from B. pertussis culture supernatants.
The proteins were purified over a fetuin affinity column as
described by Kimura et al. [87]. The proteins were dialyzed
against PBS to remove elution reagents, aliquoted and stored at
280
oC. Protein concentrations were determined by BCA assay
(Pierce) and confirmed by western blot. Activity of the toxins was
determined by ADP-ribosylation assay as previously described
[88].
Viral Strains
The mouse-adapted influenza virus A/Puerto Rico/8/34
(H1N1)(PR8) was purchased from the American Type Culture
Collection (ATCC; Manassas, VA) and grown in the allantoic fluid
of 10-day old embryonated chicken eggs (Charles River Labora-
tories, Wilmington, MA) as previously described [89]. Recombi-
nant influenza virus A/WSN/33 (H1N1) was provided by Andrew
Pekosz (Johns Hopkins University). WSN was generated using a
12-plasmid rescue system in MDCK cells as described previously
[90,91].
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All mouse procedures were performed in accordance with the
Public Health Service Policy on the Humane Care and Use of
Laboratory Animals, and with protocol 0708002 approved by the
University of Maryland, Baltimore Institutional Animal Care and
Use Committee. Six-week-old female BALB/c or C57BL/6 mice
(Charles River Laboratories) were used in our studies. Inocula of
B. pertussis or PT were prepared in 50 mL PBS (pH 7.4) and mice
were inoculated intranasally as previously described [28]. Control
mice were treated with an equal volume of PBS. Following the
bacterial infection or PT treatment, mice were challenged with
PR8 or WSN in 50 mL PBS at specified times points. Weight of the
mice was taken using a digital scale and overall appearance was
recorded. Lung tissue was harvested for determining viral titers as
previously described [92]. Briefly, mice were euthanized by carbon
dioxide inhalation at specified times and the lungs were removed
and homogenized in 2 ml of sterile PBS. The homogenate was
clarified by centrifugation at 2006g for 5 min. The liquid phase
was collected and stored at 270uC until assayed for viral titers. A
minimum of 3 mice per group was used.
Titration of virus by TCID50
Titers of viral stocks, lung homogenates and cellular superna-
tants were determined by the tissue culture infectious dose 50%
assay (TCID50) as previously described [92,93]. Briefly, half-log
dilutions of samples in DMEM-5 containing penicillin and
streptomycin were dispensed in a 96 well round bottom plate.
Madin-Darby canine kidney (MDCK) cells were seeded on top.
The following day media on the plates was changed for serum-free
DMEM with 1% BSA and TPCK trypsin (Sigma-Aldrich) and
incubated at 37uC for 4 days. Presence of virus was determined by
performing hemagglutinin activity assays using chicken red blood
cells (CRBCs). A suspension of 0.5% of CRBC was added to all
the wells and the agglutination pattern was recorded after 1 h
incubation at 4uC. The TCID50 was reported as the reciprocal of
the dilution in which 50% of the infected wells were positive for
virus calculated by the Reed-Muench method.
Protein Concentration of BAL Samples
Mice were euthanized by carbon dioxide inhalation and
dissection was performed to expose the trachea and lungs. A 20-
gauge blunt-ended needle was inserted into a small incision
towards the top of the trachea and tied in place with surgical
thread. BAL was performed by flushing the lungs two times with
0.7 ml of sterile PBS. Total protein concentration recovered in the
BAL fluid was measured by BCA assay (Pierce).
Lung Histology
For histopathological analyses of lungs, mice were euthanized
by carbon dioxide inhalation, trachea were exposed, and lungs
were inflated and fixed with 4%-buffered formalin. The lungs were
embedded in paraffin wax, sectioned and stained with H&E by the
Pathology Core Facility (University of Maryland at Baltimore),
and analyzed by light microscopy for density, composition, and
location of inflammatory infiltrates from 3 mice per time point per
group.
mTEC Infection
mTEC cultures were prepared and kindly provided by Andrew
Pekosz (Johns Hopkins University). Cells were maintained as
previously described [94]. Cells in the apical chamber were treated
with PT or PT* in DMEM containing 0.5% BSA and penicillin-
streptomycin for 24 h. Apical cells were then infected with
3,600 PFU of virus diluted in warm DMEM with 0.5% BSA
containing penicillin-streptomycin at a multiplicity of infection
(MOI) of approximately 0.01. The cells were incubated with virus
at 37uC for 1 h, the inoculum was removed, and cells were washed
three times with DMEM containing penicillin-streptomycin. After
washing, DMEM containing penicillin-streptomycin was placed in
the apical compartment. Apical supernatants were collected at the
indicated times postinfection and stored at 70uC.
IFN bioassay
BAL samples were acidified to a pH 2 and incubated at 4uC
overnight to inactivate any input virus as well as acid-labile IFNs
and other cytokines. Samples were then neutralized to pH 7 with
NaOH. Serial dilutions of each sample were added to mouse
fibroblast cells (L929) in 96-well plates and incubated for 24 h.
Encephalomyocarditis virus (EMCV) was then added at an MOI
of 5, and the cultures were incubated for 48 h before scoring the
plates for cytopathic effect (CPE). CPE was visualized by light
microscopy and BAL-treated cells were scored as the dilutions of
sample giving 50% protection from virus as compared to a
standard curve of IFNb-treated cells.
Immunoblot analysis
A549 cell lysates were prepared by direct lysis in 1x Laemmli
buffer. Proteins were separated by SDS-polyacrylamide gel
electrophoresis (12% gel) and transferred onto nitrocellulose
membranes (Bio-Rad). The blots were probed with: monoclonal
mouse antibody specific for Phospho-Stat1(Tyr701) (Cell Signal-
ing), rabbit anti-ISG15 antibody and monoclonal mouse antibody
against b-actin (BD). Horseradish peroxidase-labeled secondary
antibodies were used to detect primary antibodies and a
chemoluminescence detection system (Amersham ECL Plus) was
employed to develop the membrane. Signal quantification was
measured from exposed film utilizing GelEval software to measure
band intensity.
RNA preparation
Total RNA was extracted from whole lung tissue using the
phenol-chloroform method. Samples were homogenized in 1 ml of
RNA Stat-60 (Tel-Test, Inc.). Subsequently, 200 ml of chloroform
was added to each preparation, and the sample was centrifuged at
13,000 g for 15 min at 4uC. The aqueous phase was transferred to
a 1.5-ml tube containing 500 ml of isopropanol, and the samples
were stored at 220uC overnight. The samples were centrifuged at
13,000 g for 15 min at 4uC, and the supernatants were removed
from the RNA pellets. The RNA pellets were washed twice with
80% ethanol and centrifuged, and ethanol was removed from the
pellets. The samples were dried with a DNA Speedvac (Savant) at
a low temperature for 15 min until the pellets became transparent.
Each pellet was resuspended in 50 ml of nuclease-free H2O and
placed in a 65uC water bath for 30 min. RNA samples were
further cleaned up using the Qiagen RNeasy Mini Kit according
to manufacturers protocol.
Microarray Expression Profiling
Mouse gene expression was examined with the GeneChip
Mouse Gene 1.0 ST Array (Affymetrix). RNA quality control,
sample labeling, GeneChip hybridization and data acquisition
were performed at the Biopolymer/Genomics Core Facility at the
University of Maryland School of Medicine. Quantity and purity
of the RNA samples was determined by examining the 260/280
ratio (Nanodrop, Thermo Scientific, Worcester, MA) and via
analysis on the Experion RNA StdSens Analysis kit (Bio-Rad,
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was reverse transcribed to cDNA, converted and amplified to
antisense cRNA and labeled with biotin in an in vitro transcription
reaction according to the manufacturer’s protocol (Affymetrix,
Santa Clara, CA). Targets were hybridized to Affymetrix Mouse
Gene 1.0 ST Array, which contains approximately 27 probes
spread across the length of 28,853 genes. All arrays were scanned
at the same time on the Affymetrix Gene-Chip Scanner 3000G
and the resulting .cel files were used in the analysis.
The input files were normalized with full quantile normalization
[95]. For each input array, for each probe expression value, the
array ith percentile probe value was replaced with the average of
all array ith percentile points. Next, the 906,151 probes were
transformed into analysis values. Probes with a GC count less than
6 and greater than 17 were excluded from the analysis. The
intensity values for probes included in the analysis were
transformed by taking the Natural Logarithm of 0 plus the probe
score. Probes were stratified by CG content and defined in the
MouseGene10ST_antigenomic.bgp file. Each probe score was
corrected for background by subtracting the median expression
score of background probes with similar GC content. Expression
scores for each probe-set were defined as the median of the probe
expression scores. Differential gene expression was determined
using analysis of variance (XRay v3.98; Biotique Systems, Reno,
NV). Because of the large number of statistical tests performed, a
False Discovery Rate (FDR) correction was performed to correct
p-values. We defined a differentially expressed gene as one with a
1.5 fold change from control and an FDR-corrected p-value of less
than 0.05. Data were analyzed through the use of Ingenuity
Pathways Analysis (IngenuityH Systems, www.ingenuity.com). The
Functional Analysis identified the biological functions and/or
diseases that were most significant to the data set. Molecules from
the dataset that met the 1.5 fold change cutoff and P=0.05 and
were associated with biological functions and/or diseases in
Ingenuity’s Knowledge Base were considered for the analysis.
Right-tailed Fisher’s exact test was used to calculate a p-value
determining the probability that each biological function and/or
disease assigned to that data set is due to chance alone.
Canonical pathways analysis identified the pathways from the
Ingenuity Pathways Analysis library of canonical pathways that
were most significant to the data set. Molecules from the data set
that met the 1.5 fold change cutoff and P=0.05 and were
associated with a canonical pathway in Ingenuity’s Knowledge
Base were considered for the analysis. The significance of the
association between the data set and the canonical pathway was
measured in 2 ways: 1) a ratio of the number of molecules from the
data set that map to the pathway divided by the total number of
molecules that map to the canonical pathway is displayed; 2)
Fisher’s exact test was used to calculate a p-value determining the
probability that the association between the genes in the dataset
and the canonical pathway is explained by chance alone.
Cytokine measurements
Mice were euthanized and BAL was performed as described
above. Resident cells were spun out by centrifugation 3 times at
13,000 g for 1 min. The supernatants were stored at 280uC, and
multiplex cytokine array (Luminex 100 System) was performed for
IL-1b, IL-2, IL-6, KC, IL-10, IL-12 (p40), IFN-c, TNF-a, MCP-1,
and RANTES at the UMB Cytokine Core Laboratory.
Flow cytometric analysis
BAL samples were harvested as described above and centri-
fuged at 13,0006g for 1 min to recover airways cells. Cells were
washed with staining buffer (1% FBS in PBS) and immunostained
with fluorescently labeled antibodies (eBioscience) for CD11b
(Clone M1/70), CD11c (Clone N418), Gr-1 (Clone RB6-8C5),
and NK (Clone 14B11), for 30 min at 4uC and then washed twice
in staining buffer. Cell samples were then fixed with 4%
paraformaldehyde for 15 min at room temperature. Events were
collected on a LSRII flow cytometer (Becton Dickinson) driven by
FACSDiva software (Becton Dickinson), and analyzed using
FlowJo software (Tree Star). Data were collected for 10,000 viable
cells selected by forward and side scatter. Cellular profiles were










All statistical analysis was performed using GraphPad Prism
version 4 for Macintosh (GraphPad Software, San Diego,
California, USA). Data were expressed as the mean 6 s.d.
Statistical significance of differences between experimental groups
was determined using the student’s t-test to compare two normally-
distributed samples or ANOVA to compare multiple samples.
Kaplan-Meier log-rank test was used for survival analyses. P values
.0.05 were considered not to be significant. All data shown are
representative of at least two independent experiments,
Supporting Information
Figure S1 Effect of PT treatment on survival rates of
mice infected with influenza. Groups of BALB/c mice were
intranasally treated with 100 ng of PT and 24 h later inoculated
with influenza PR8. (A) Survival of mice inoculated with a
moderate (500 PFU) or (C) large (1500 PFU) dose of influenza
virus. (B, D) Weight loss of mice in panel A and C respectively.
n=8 mice/treatment group *Significantly different from control
(P,0.05).
(TIF)
Figure S2 Effect of PT treatment on BAL protein
concentration in influenza virus-infected mice. Groups
of BALB/c mice were intranasally treated with 100 ng of PT
(control mice were treated with PBS) and 24 h later inoculated
with influenza PR8 (600 PFU). BAL fluid was recovered from
these mice on days 2, 6 and 8 post-virus inoculation and total
protein concentration was determined. n=4 mice/treatment
group *Significantly different from control PR8-infected mice
(P,0.05); **P,0.01.
(TIF)
Figure S3 PT does not suppress type I IFN responses.
(A,B) BALB/c mice (n=3) were treated with 100 ng of PT or an
equal volume of PBS and infected with influenza PR8 (600 PFU)
24 h later. BAL fluid was recovered and assayed by (A) ELISA for
IFN-a or (B) type I IFN bioassay at the indicated times post virus
inoculation. *Significantly different from control (P,0.05). (C)
Immunoblot analysis of lysates from A549 cells pretreated with or
without 1 nM PT for 24 h and stimulated with 1000 U human
IFN A/D and probed with anti-phospho-STAT1 (Tyr701)
antibody. (D) Normalized pY-STAT1 band intensities. (E)
Immunoblot analysis of lysates from A549 cells treated with or
without 1 nM PT for 24 h and infected with influenza PR8
(MOI=1) and probed with anti-ISG15 antibody. (F) Normalized
ISG15 band intensities. Immunoblots are representative of two
experiments. *Significantly different from control (P,0.05).
(TIF)
Table S1 Biological functions significantly affected by PT
pretreatment in influenza virus-infected mice.
(PDF)
B. pertussis Exacerbates Secondary Influenza
PLoS ONE | www.plosone.org 13 April 2011 | Volume 6 | Issue 4 | e19016Table S2 Genes differentially-regulated by PT pretreatment in
influenza virus-infected mice at 12 h post-inoculation.
(PDF)
Table S3 Genes differentially-regulated by PT pretreatment in
influenza virus-infected mice at 36 h post-inoculation.
(PDF)
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